Connect with us

Hi, what are you looking for?

Business

Analysts Set Adaptive Biotechnologies Price Target at $13.22

Adaptive Biotechnologies Corporation (NASDAQ: ADPT) has received a consensus rating of “Moderate Buy” from ten analysts, according to MarketBeat.com. This rating reflects a mix of recommendations, with one analyst issuing a sell rating, one a hold rating, and eight analysts recommending a buy.

The average price target for the stock is currently set at $13.22, based on reports from brokers who updated their coverage over the past year. Notably, Piper Sandler recently increased its price target for Adaptive Biotechnologies from $13.00 to $15.00, assigning an “overweight” rating. Similarly, Guggenheim initiated coverage with a buy rating and a target price of $20.00.

As part of the research updates, Craig Hallum also provided a buy rating with a target of $15.00, while JPMorgan Chase & Co. raised its target from $10.00 to $14.00, maintaining an “overweight” rating. In contrast, Weiss Ratings reaffirmed a “sell (d-)” rating on the stock.

Earnings Report Highlights Performance

On August 5, 2023, Adaptive Biotechnologies announced its quarterly earnings, reporting earnings per share (EPS) of ($0.17), surpassing the consensus estimate of ($0.24) by $0.07. The company generated revenue of $49.94 million, exceeding expectations, and marking a 36.3% increase year-over-year. The firm recorded a negative net margin of 59.07% and a negative return on equity of 60.93%.

Looking ahead, analysts predict that the company will post an EPS of ($0.92) for the current year.

Institutional Investors Increase Holdings

In recent months, several institutional investors have adjusted their holdings in Adaptive Biotechnologies. Two Sigma Investments LP raised its stake by 251.1% in the fourth quarter, now owning 183,838 shares valued at approximately $1.1 million. Two Sigma Advisers LP also increased its shareholding by 396.2%, acquiring an additional 41,200 shares for a total of 51,600 shares worth around $309,000.

Other notable investors include Squarepoint Ops LLC, which raised its stake by 265.3%, and California State Teachers Retirement System, which boosted its holdings by a remarkable 1,060.5%. Collectively, institutional investors hold 99.17% of the company’s stock.

Adaptive Biotechnologies Corporation specializes in developing an immune medicine platform aimed at diagnosing and treating various diseases. The company utilizes an immunosequencing platform that combines proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data, effectively decoding the adaptive immune system.

You May Also Like

Technology

Tesla (TSLA) recently reported a year-over-year drop in second-quarter deliveries, yet the market responded with optimism, pushing the stock up by 5%. This unexpected...

Health

The All England Lawn Tennis Club in London experienced its hottest-ever opening day on Monday, as the prestigious Wimbledon tournament kicked off under unprecedented...

Technology

In a bold reimagining of the DC Universe, director James Gunn has introduced a significant narrative element in his latest film, which reveals that...

Science

Look out, daters: a new toxic relationship trend is sweeping through the romantic world, leaving many baffled and heartbroken. Known as “Banksying,” this phenomenon...

Technology

Former Speaker of the House Nancy Pelosi has recently made headlines with her latest investment in the tech sector. According to official filings, she...

Entertainment

A new documentary series titled “Animals on Drugs” is set to premiere on the Discovery Channel on July 28, 2023. The three-part series follows...

Entertainment

Netflix’s eagerly anticipated talent competition Building the Band is set to premiere on July 9, promising an emotional journey for viewers. This series, centered...

Technology

The answer to today’s NYT Wordle, dated August 8, 2025, is the verb IMBUE. This word, which means “to fill or saturate,” features three...

World

The first dose of the hepatitis B vaccine is recommended at birth, a practice that has come under scrutiny following recent comments by Health...

Technology

The Evo 2025 tournament is set to take place from August 1 to August 3, 2025, showcasing some of the most popular fighting games...

Sports

ZAGREB, Croatia — A concert by Marko Perkovic, a right-wing Croatian singer known for his controversial views, attracted tens of thousands of fans to...

Lifestyle

The upcoming TRNSMT 2025 festival is set to take place from July 7 to July 9, 2025, at Glasgow Green, and organizers have released...

Sports

As the summer of 2025 unfolds, the video game industry is set to deliver a diverse array of new releases that promise to captivate...

Politics

Billionaire hedge fund manager Bill Ackman faced significant backlash following his professional tennis debut at the Hall of Fame Open in Newport, Rhode Island,...

Business

Erin Dana Lichy, a prominent cast member of “Real Housewives of New York,” has officially settled into her dream home, a grand townhouse located...

Entertainment

While the echoes of Summer Game Fest 2025 and the Xbox Games Showcase still resonate, Xbox has already set its sights on the next...

Copyright © All rights reserved. This website provides general news and educational content for informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the information presented. The content should not be considered professional advice of any kind. Readers are encouraged to verify facts and consult appropriate experts when needed. We are not responsible for any loss or inconvenience resulting from the use of information on this site.